Bcl-2 family inhibitors sensitize human cancer models to therapy

BH3 mimetics, targeting the Bcl-2 family anti-apoptotic proteins, represent a promising therapeutic opportunity in cancers. ABT-199, the first specific Bcl-2 inhibitor, was approved by FDA for the treatment of several hematological malignancies. We have recently discovered IS21, a novel pan BH3 mime...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentini, Elisabetta, Di Martile, Marta, Brignone, Matteo, Di Caprio, Marica, Manni, Isabella, Chiappa, Michela, Sergio, Ilaria, Chiacchiarini, Martina, Bazzichetto, Chiara, Conciatori, Fabiana, D’Aguanno, Simona, D’Angelo, Carmen, Ragno, Rino, Russillo, Michelangelo, Colotti, Gianni, Marchesi, Francesco, Bellone, Maria Laura, Dal Piaz, Fabrizio, Felli, Maria Pia, Damia, Giovanna, Del Bufalo, Donatella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352371/
https://www.ncbi.nlm.nih.gov/pubmed/37460459
http://dx.doi.org/10.1038/s41419-023-05963-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352371/
https://www.ncbi.nlm.nih.gov/pubmed/37460459
http://dx.doi.org/10.1038/s41419-023-05963-1

Ejemplares similares